Blocking of nonspecific IgG in indirect radioimmunoassay for detecting Ascaris suum antigens.

M. Rhodes,P. K. Baker

DOI: https://doi.org/10.1016/0304-4017(86)90130-5

IF: 2.821

1986-04-01

Veterinary Parasitology

Abstract:

What problem does this paper attempt to address?

Safety evaluation of human umbilical cord-mesenchymal stem cells in type 2 diabetes mellitus treatment: A phase 2 clinical trial

Xiao-Fen Lian,Dong-Hui Lu,Hong-Li Liu,Yan-Jing Liu,Yang Yang,Yuan Lin,Feng Xie,Cai-Hao Huang,Hong-Mei Wu,Ai-Mei Long,Chen-Jun Hui,Yu Shi,Yun Chen,Yun-Feng Gao,Fan Zhang

DOI: https://doi.org/10.12998/wjcc.v11.i21.5083

2023-07-26

Abstract:Background: Progressive pancreatic β cell dysfunction is a fundamental aspect of the pathology underlying type 2 diabetes mellitus (T2DM). Recently, mesenchymal stem cell (MSC) transplantation has emerged as a new therapeutic method due to its ability to promote the regeneration of pancreatic β cells. However, current studies have focused on its efficacy, and there are few clinical studies on its safety. Aim: To evaluate the safety of human umbilical cord (hUC)-MSC infusion in T2DM treatment. Methods: An open-label and randomized phase 2 clinical trial was designed to evaluate the safety of hUC-MSC transplantation in T2DM in a Class A hospital. Ten patients in the placebo group received acellular saline intravenously once per week for 3 wk. Twenty-four patients in the hUC-MSC group received hUC-MSCs (1 × 106 cells/kg) intravenously once per week for 3 wk. Diabetic clinical symptoms and signs, laboratory findings, and imaging findings were evaluated weekly for the 1st mo and then at weeks 12 and 24 post-treatment. Results: No serious adverse events were observed during the 24-wk follow-up. Four patients (16.7%) in the hUC-MSC group experienced transient fever, which occurred within 24 h after the second or third infusion; this did not occur in any patients in the placebo group. One patient from the hUC-MSC group experienced hypoglycemic attacks within 1 mo after transplantation. Significantly lower lymphocyte levels (weeks 2 and 3) and thrombin coagulation time (week 2) were observed in the hUC-MSC group compared to those in the placebo group (all P < 0.05). Significantly higher platelet levels (week 3), immunoglobulin levels (weeks 1, 2, 3, and 4), fibrinogen levels (weeks 2 and 3), D-dimer levels (weeks 1, 2, 3, 4, 12, and 24), and neutrophil-to-lymphocyte ratios (weeks 2 and 3) were observed in the hUC-MSC group compared to those in the placebo group (all P < 0.05). There were no significant differences between the two groups for tumor markers (alpha-fetoprotein, carcinoembryonic antigen, and carbohydrate antigen 199) or blood fat. No liver damage or other side effects were observed on chest X-ray. Conclusion: Our study suggested that hUC-MSC transplantation has good tolerance and high safety in the treatment of T2DM. It can improve human immunity and inhibit lymphocytes. Coagulation function should be monitored vigilantly for abnormalities.
Therapeutic Efficacy Of Umbilical Cord-Derived Mesenchymal Stem Cells In Patients With Type 2 Diabetes

Li-Xue Guan,Hui Guan,Hai-Bo Li,Cui-Ai Ren,Lin Liu,Jin-Jin Chu,Long-Jun Dai

DOI: https://doi.org/10.3892/etm.2015.2339

IF: 2.7

2015-01-01

Experimental and Therapeutic Medicine

Abstract:Type 2 diabetes (T2D) is characterized by progressive and inexorable beta-cell dysfunction, leading to insulin deficiency. Novel strategies to preserve the remaining beta-cells and restore beta-cell function for the treatment of diabetes are urgently required. Mesenchymal stem cells (MSCs) have been exploited in a variety of clinical trials aimed at reducing the burden of immune-mediated disease. The aim of the present clinical trial was to assess the safety and efficacy of umbilical cord-derived MSC (UCMSC) transplantation for patients with T2D. The safety and efficacy of UCMSC application were evaluated in six patients with T2D during a minimum of a 24-month follow-up period. Following transplantation, the levels of fasting C-peptide, the peak value and the area under the C-peptide release curve increased significantly within one month and remained high during the follow-up period (P<0.05). Three of the six patients became insulin free for varying lengths of time between 25 and 43 months, while the additional three patients continued to require insulin injections, although with a reduced insulin requirement. Fasting plasma glucose and 2-h postprandial blood glucose levels were relatively stable in all the patients following transplantation. There was no immediate or delayed toxicity associated with the cell administration within the follow-up period. Therefore, the results indicated that transplantation of allogeneic UCMSCs may be an approach to improve islet function in patients with T2D. There were no safety issues observed during infusion and the long-term monitoring period.
Study of The Phytochemical Analysis And Antimicrobial Activity of Dodonaea Viscosa

V. Ramamurthy,D. Rajeswari,R. Gowri,M. K. Vadivazhagi,G. Jayanthi,S. Raveendran

Abstract:Ethanol extracts of Dodonaea viscosa were used traditionally in India for the treatment of skin diseases. The present study was investigated for in vitro antimicrobial activity against pathogens namely Staphylococcus aureus, Bacillus subtilis, Streptococcus pyogenes, Pseudomonas auroginosa, Klebsiella pnemonia, Aspergillus niger, Trichoderma viride and Candida albicans using the agar well diffusion method. A parallel study was performed to identify the distribution and the concentration of the phytocompounds in the roots and leaves of this plant. For this purpose alcoholic extracts were prepared from each part of the plant and studied them separately. Among the leaf extracts of D. viscosa possess the highest inhibitory activity then the root extracts. The results revealed that the plant leaf extract possessed the highest inhibitory activity against the bacteria and fungi.
Effect of Htimp-1 Overexpression in Human Umbilical Cord Mesenchymal Stem Cells on the Repair of Pancreatic Islets in Type-1 Diabetic Mice

Yu Bao,Zhengyan Zhao,Huihui Gao

DOI: https://doi.org/10.1002/cbin.11548

IF: 4.473

2021-01-01

Cell Biology International

Abstract:Mesenchymal stem cells (MSCs) have been suggested for pancreatic islet repair in Type 1 diabetes mellitus (T1DM). This study aimed to investigate the effect of human umbilical cord MSCs (hUC-MSCs) transfected with tissue inhibitors of matrix metalloproteinase (TIMP)-1 on the regeneration of beta-cell islets in vitro and in vivo. hUC-MSCs were isolated, cultured, and transfected with lentiviruses for the overexpression of hTIMP-1. An in vitro coculture system of hUC-MSCs and streptozotocin-induced islets was established to examine the morphology, apoptosis, and insulin secretion of the cocultured islets. Diabetic mouse models were injected with lenti-TIMP-1-enhanced green fluorescent protein (EGFP)-hUC-MSCs to test the effect of hTIMP-1 on insulin levels and glucose tolerance in vivo. The expression of insulin and glucagon was evaluated by immunofluorescence staining. The results showed that coculture with hUC-MSCs or Lenti-TIMP-1-EGFP-hUC-MSCs improved islet viability rates. Lenti-TIMP-1-EGFP-hUC-MSC coculture increased the insulin and C-peptide secretion function of the cultured islets and increased the secretion of tumor necrosis factor-beta 1, interleukin-6, IL-10, and hTIMP-1. hUC-MSCs, especially those transfected with Lenti-hTIMP-1-EGFP, showed a strong protective effect in diabetic mice by alleviating weight loss and improving glucose and insulin metabolism. In addition, transplantation rescued islet histology and function in vivo. The overexpression of TIMP-1 by hUC-MSCs seems to exert beneficial effects on pancreatic islet cells. In conclusion, this study may provide a new perspective on the development of hUC-MSC-based cell transplantation therapy for T1DM.
Efficacy of Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Type 2 Diabetes Assessed by Retrospective Continuous Glucose Monitoring

Li Zang,Yijun Li,Haojie Hao,Jiejie Liu,Qian Zhang,Fei Gao,Haibin Wang,Yulong Chen,Weijun Gu,Jin Du,Junhua Meng,Saichun Zhang,Zhaohui Lyu,Jingtao Dou,Yiming Mu

DOI: https://doi.org/10.1093/stcltm/szad060

2023-12-18

Abstract:Umbilical cord-derived mesenchymal stem cells (UC-MSCs) have been proved a promising clinical strategy for the treatment of diabetes, and time in range (TIR) has been demonstrated a new metric of glycemic control links to diabetes complications. To further assess the therapeutic effect of UC-MSCs on TIR, a phase II study investigating the efficacy of UC-MSCs in Chinese adults with type 2 diabetes (T2D) assessed by retrospective continuous glucose monitoring (CGM) was conducted. In this randomized and placebo-controlled trial, a total of 73 patients were randomly assigned to receive intravenous infusion of UC-MSCs (n = 37) or placebo (n = 36) 3 times at 4-week intervals and followed up for 48 weeks. The primary endpoint was the changes in TIR and glycosylated hemoglobin (HbA1c). TIR and HbA1c were both significantly improved in UC-MSCs and placebo groups after 48 weeks of therapy compared with baseline. Compared with placebo group, UC-MSCs group exhibited more pronounced changes at 9 and 48 weeks from baseline in TIR (26.54 vs. 15.84 and 21.36 vs. 6.32) and HbA1c (-1.79 vs. -0.96 and -1.36 vs. -0.51). More patients in UC-MSCs group achieved the glycemic control target of TIR ≥ 70% and HbA1c < 7% at 9 and 48 weeks than in placebo group (59.5% vs. 27.8% and 43.2% vs. 11.1%). The C-peptide area under the curve (AUCC-pep) was an independent risk factor associated with efficacy in T2D undergoing UC-MSCs intervention. These results illustrate that UC-MSCs administration via intravenous infusion is an effective approach for ameliorating TIR.
Umbilical cord mesenchymal stem cells transplantation for newly-onset type 1 diabetes

Wen-long Yu,Hong Gao,Xiao-long Yu,Li Wang,Sheng-li Yan,Yan-gang Wang

DOI: https://doi.org/10.3969/j.issn.1673-8225.2011.23.042

2011-01-01

Abstract:BACKGROUND: Autologous hematopoietic stem cells transplantation can enhance function of beta cells of islet and prolong time independent of insulin. OBJECTIVE: To observe the clinical efficacy of human umbilical cord mesenchymal stem cells (hUCMSCs) transplantation in treatment of newly-onset type 1 diabetes. METHODS: A total of 12 patients with newly-onset type 1 diabetes mellitus (less than 3 months) were selected. Six cases were treated by hUCMSCs transplantation and insulin, and the other 6 were treated by insulin alone. Before and 9 months after transplantation, fasting and postprandial blood glucose, insulin dosage, C peptide, HbA1c changes and adverse events were measured. RESULTS AND CONCLUSION: Patients were followed up for 9 months. Fasting blood glucose, HbA1c and C peptide levels were significantly improved in stem cell therapy group compared with control group. In addition to significantly reduced C peptide levels, other indexes remained unchanged in control group. Results showed that hUCMSCs transplantation has positive effects on treatment of newly-onset type l diabetes.
Clinical efficacy of autologous stem cell transplantation for the treatment of patients with type 2 diabetes mellitus: a meta-analysis.

Zheng-Xu Wang,Jun-Xia Cao,Duo Li,Xiao-Yan Zhang,Jin-Long Liu,Jun-Li Li,Min Wang,Yishan Liu,Bei-Lei Xu,Hai-Bo Wang

DOI: https://doi.org/10.1016/j.jcyt.2015.02.014

IF: 6.196

2015-01-01

Cytotherapy

Abstract:In this study, we investigate whether bone marrow mononuclear cells (BM-MNC) or peripheral blood mononuclear cells (PB-MNC) have therapeutic efficacy in type 2 diabetes (T2D).Search terms included stem cell, bone marrow cell, peripheral blood cell, umbilical cord blood and T2D in MEDLINE, the Cochrane Controlled Trials Register, EMBASE, the Wanfang Database, the China Science and Technology Periodical Database and China Journal Net.Fifteen trials met our inclusion criteria (n = 497). One group included 266 cases with BM-MNC therapy and the other group contained 231 cases with PB-MNC treatment. Glycosylated hemoglobin was decreased after BM-MNC or PB-MNC therapy compared with that before (12 months: P < 0.001; 6 months: P < 0.001; 3 months: P < 0.05). Fasting plasma glucose was reduced in BM-MNC therapy group compared with control after 12-month follow-up (P < 0.001) and after BM-MNC therapy compared with that before (9 months: P < 0.001) but was not obvious in other stages. Meanwhile, the analysis showed that C-peptide level increased after BM-MNC and PB-MNC therapy compared with the control therapy (12 months: P < 0.001) and with that before therapy (6 months: P < 0.05). Insulin requirement reduction was also observed in patients receiving BM-MNC therapy (3, 6, 9 and 12 months: P < 0.05).To a certain extent, BM-MNC or PB-MNC therapy for T2D demonstrated superiority of glycemic control, increased insulin biosynthesis and elevated insulin secretion from existing β-cells and might prevent islet cell loss.
Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial

Li Zang,Yijun Li,Haojie Hao,Jiejie Liu,Yu Cheng,Bing Li,Yaqi Yin,Qian Zhang,Fei Gao,Haibin Wang,Shi Gu,Jia Li,Fengxiang Lin,Yingfei Zhu,Guanglei Tian,Yulong Chen,Weijun Gu,Jin Du,Kang Chen,Qinghua Guo,Guoqing Yang,Yu Pei,Wenhua Yan,Xianling Wang,Junhua Meng,Saichun Zhang,Jianming Ba,Zhaohui Lyu,Jingtao Dou,Weidong Han,Yiming Mu

DOI: https://doi.org/10.1186/s13287-022-02848-6

2022-05-04

Abstract:Background To determine the efficacy and safety of umbilical cord-derived mesenchymal stem cells (UC-MSCs) in Chinese adults with type 2 diabetes mellitus (T2DM). Methods In this single-center, double-blinded, randomized, placebo-controlled phase II trial, 91 patients were randomly assigned to receive intravenous infusion of UC-MSCs ( n = 45) or placebo ( n = 46) three times with 4-week intervals and followed up for 48 weeks from October 2015 to December 2018. The primary endpoint was the percentage of patients with glycated hemoglobin (HbA1c) levels of < 7.0% and daily insulin reduction of ≥ 50% at 48 weeks. Additional endpoints were changes of metabolic control, islet β-cell function, insulin resistance, and safety. Results At 48 weeks, 20% of the patients in the UC-MSCs group and 4.55% in the placebo group reached the primary endpoint ( p < 0.05, 95% confidence interval (CI) 2.25–28.66%). The percentage of insulin reduction of the UC-MSCs group was significantly higher than that of the placebo group (27.78% versus 15.62%, p < 0.05). The levels of HbA1c decreased 1.31% (9.02 ± 1.27% to 7.52 ± 1.07%, p < 0.01) in the UC-MSCs group, and only 0.63% in the placebo group (8.89 ± 1.11% to 8.19 ± 1.02%, p ˃0.05; p = 0.0081 between both groups). The glucose infusion rate (GIR) increased significantly in the UC-MSCs group (from 3.12 to 4.76 mg/min/kg, p < 0.01), whereas no significant change was observed in the placebo group (from 3.26 to 3.60 mg/min/kg, p ˃ 0.05; p < 0.01 between both groups). There was no improvement in islet β-cell function in both groups. No major UC-MSCs transplantation-related adverse events occurred. Conclusions UC-MSCs transplantation could be a potential therapeutic approach for Chinese adults with T2DM. Trial registration This study was registered on ClinicalTrials.gov (identifier: NCT02302599).

cell biology,medicine, research & experimental,cell & tissue engineering
Stem cell transplantation for the treatment of diabetic foot

Wang Guang-yu,Zhu Lü-yun,Ma Li-cheng,Hu Li-ye,Li Xiao-ling,Yang Shao-ling,Shan Wei,Hou Rong-rong

DOI: https://doi.org/10.3969/j.issn.2095-4344.2013.01.028

2013-01-01

Abstract:BACKGROUND: Autologous bone marrow and umbilical blood mononuclear cell transplantation can improve the clinical symptoms caused by ischemic lesions and peripheral nerve injury, and have good effect on diabetic foot. Umbilical cord-derived mesenchymal stem cells have their own advantages when compared with bone marrow stem cells and umbilical cord blood stem cells.OBJECTIVE: To observe the effect of umbilical cord-derived mesenchymal stem cells on diabetic foot ischemic lesions and peripheral nerve injury. METHODS: Thirty-two patients with diabetic foot who received umbilical cord-derived mesenchymal stem cell transplantation from 2010 to 2012 were selected. Umbilical cord-derived mesenchymal stem cells were intramuscularly injected into the bilateral lower extremities with 3 cm distance between two injection sites after dilution. The number of implanted cells was (5.02±1.37) ×10 8 per leg. The lower extremity ischemia and lower extremity peripheral neuropathy were evaluated at 3 and 6 months after injection. The CMKI database was searched for the literatures in order to analyze the research situation of stem cell transplantation for the treatment of diabetic foot in China. RESULTS AND CONCLUSION: There was no significant difference in ankle/brachial index after treatment. The pain score and the apathetic score were significantly improved at 6 months after transplantation. There were significant differences in angina cruris, skin temperature and transcutaneous oxygen partial pressure after 3 or 6 months of treatment. After treatment for 6 months, there were significant differences in rational symptom score, clinical examination score and vibration perception threshold. There were no significant differences in the conduction velocity of motor/sensory nerves of peroneal nerve and tibial nerve at 3 months after transplantation when compared with those before transplantation (P > 0.05), and there were significant differences at 6 months after transplantation when compared with those before transplantation (P < 0.05). The clinical symptoms and objective indexes of diabetic ischemic lesions and peripheral neuropathy can be improved by umbilical cord- derived mesenchymal stem cells. Literatures analysis has shown that the therapeutic effect in the existing research is satisfactory, and the transplantation method in most researches is consistent with that in this research.
Umbilical cord blood stem cell transplantation for the treatment of diabetic foot in 23 cases

Lü-yun Zhu,Guang-yu Wang,Li-cheng Ma,Li-ye Hu,Xiao-ling Li,Shao-ling Yang,Wei Shan,Rong-rong Hou

DOI: https://doi.org/10.3969/j.issn.1673-8225.2012.01.038

2012-01-01

Abstract:Background: Transplantation of autologous bone-marrow mononuclear cells or umbilical cord derived mesenchymal stem cells for treatment of diabetic foot has been widely developed at present, which showed good curative effect on ischemic lesions and peripheral neuropathy. Objective: To observe the effect of umbilical cord derived mononuclear cells on diabetic ischemic lesions and peripheral neuropathy. Methods: Twenty-three patients with diabetic foot received umbilical cord derived mononuclear cells injection into both lower extremities intramuscular (1-3 mL/site) for 3 cm distance after dilution. The number of implanted cells was 1.23×108 -1.06×109 per leg (totally 38 limbs). Results and Conclusion: There was no significant difference in ankle/brachial index after treatment. There were significant differences in angina cruris, skin temperature and transcutaneous oxygen partial pressure after 3 or 6 months treatment. After treatment for 6 months, the pain score and thermoesthesia score were improved and there were significant differences in rational symptom score, clinical examination score, the value of pallesthetic sensibility and the conduction velocity of motor/sensory nerves. The clinical symptoms and objective indexes of diabetic ischemic lesions and peripheral neuropathy were improved after umbilical cord derived mononuclear cells implantation.
Comparison of therapeutic effects of mesenchymal stem cells from umbilical cord and bone marrow in the treatment of type 1 diabetes

Wei Zhang,Qing Ling,Bin Wang,Kai Wang,Jianbo Pang,Jing Lu,Yan Bi,Dalong Zhu

DOI: https://doi.org/10.1186/s13287-022-02974-1

2022-01-01

Stem Cell Research & Therapy

Abstract:Background The therapeutic potential of mesenchymal stem cells (MSCs) in type 1 diabetes (T1D) has been demonstrated in both preclinical and clinical studies. MSCs that have been used in research on T1D are derived from various tissue sources, with bone marrow (BM) and umbilical cord (UC) tissues being the most commonly used. However, the influence of tissue origin on the functional properties and therapeutic effects of MSCs in T1D remains unclear. This study aimed to compare the therapeutic efficacy of UC-MSCs and BM-MSCs in a mouse model of T1D as well as in patients with T1D. Methods In non-obese diabetic (NOD) mice, the development of diabetes was accelerated by streptozotocin injections. Thereafter, diabetic mice were randomized and treated intravenously with UC-MSCs, BM-MSCs or phosphate-buffered saline as a control. Blood glucose and serum insulin were measured longitudinally after transplantation. At 14 days post-transplantation, pancreatic tissues were collected to assess insulitis and the β-cell mass. Flow cytometry was performed to evaluate the composition of T lymphocytes in the spleen and pancreatic lymph nodes of the NOD mice. In our retrospective study of patients with T1D, 28 recipients who received insulin therapy alone or a single transplantation of UC-MSCs or BM-MSCs were enrolled. The glycaemic control and β-cell function of the patients during the first year of follow-up were compared. Results In NOD mice, UC-MSC and BM-MSC transplantation showed similar effects on decreasing blood glucose levels and preserving β cells. The regulation of islet autoimmunity was examined, and no significant difference between UC-MSCs and BM-MSCs was observed in the attenuation of insulitis, the decrease in T helper 17 cells or the increase in regulatory T cells. In patients with T1D, MSC transplantation markedly lowered haemoglobin A1c (HbA1c) levels and reduced insulin doses compared to conventional insulin therapy. However, the therapeutic effects were comparable between UC-MSCs and BM-MSCs, and they also exerted similar effects on the endogenous β-cell function in the patients. Conclusion In conclusion, both UC-MSCs and BM-MSCs exhibited comparable therapeutic effects on improving glycaemic control and preserving β-cell function in T1D. Considering their abundance and higher cell yields, UC-MSCs appear to be more promising than BM-MSCs in clinical applications. Trial registration NCT02763423. Registered on May 5, 2016—Retrospectively registered, https://www.clinicaltrials.gov/ .
Human umbilical cord-derived mesenchymal stem cell transplantation for treatment for onset type 1 diabetes mellitus

Yu Wen-long,Xu Wei,Yu Jiang-su,Wang Li,Gao Hong,Wang Yan-gang

DOI: https://doi.org/10.3969/j.issn.2095-4344.2013.19.009

2013-01-01

Abstract:BACKGROUND: Mesenchymal stem cells have self-replicating, immune tolerance and tissue repair characteristics. Type 1 diabetes mellitus is an autoimmune disease mainly resulting from islet beta-cell damage. In view of this, mesenchymal stem cells can be considered to prevent and treat type 1 diabetes mellitus. OBJECTIVE: To observe the effect of umbilical cord mesenchymal stem cell transplantation on the newly-onset type 1 diabetic mice (NOD mice). METHODS: Type 1 diabetes model mice (NOD mice) were selected and divided into control group (Group A, mice without onset were injected with normal saline 1 mL into the tail vein), interventional group (Group B, onset mice were injected with 1 mL stem cells into the tail vein, 1×10 6 cells per mouse), and group without injection of umbilical cord mesenchymal stem cells after onset (Group C, onset mice were injected with normal saline 1 mL into the tail vein). Three months later, blood glucose and daily insulin dose were detected; the number and proportion of CD4+, CD8+T cells and CD4+CD25+regulatory T cells were determined using a flow cytometry; levels of interleukin-2, interleukin-10 and tumor necrosis factor alpha were detected using enzyme linked immunosorbent assay; and fasting and 2-hour postprandial C-peptide levels were detected using enzyme-linked immunosorbent double antibody sandwich method. Islet morphology and lymphocyte infiltration were observed based on pathological sections. The number and size of the islet α and β cells were determined by using immunohistochemical method. RESULTS AND CONCLUSION: (1) Compared with the group C, the immunohistochemical results confirmed that infiltration of lymphocytes in the group B was significantly reduced, the structure of islet α and β cells was more complete and the number of α and β cells was significantly increased and consistent. (2) Compared with the group C, the CD4+T cell number and the rate of CD4+/CD8+T cells in the group B were lower (P<0.05), while the number of CD4+CD25+regulatory T cells in the group B was higher (P<0.01). (3) Compared with the group C, the tumor necrosis factor-α level was significantly lower in the group B, but interleukin-10 level was increased in the group B (P<0.01). (4) Compared with the group C, the group B had lower blood glucose level and insulin dose, but a higher C-peptide level (P<0.05). It is indicated that umbilical cord-derived mesenchymal stem cells have a positive effect on the treatment of onset type 1 diabetes mellitus, which can reduce blood glucose level and insulin dose.
[The impact of human umbilical cord-derived mesenchymal stem cells on the pancreatic function of type 2 diabetic mice and their regulatory role on NLRP3 inflammasomes]

J Wang,Y Q Yin,Y Cheng,B Li,W L Su,S Y Yu,J Xue,Y L Gu,H X Zhang,L X Zhang,L Zang,Y M Mu

DOI: https://doi.org/10.3760/cma.j.cn112138-20221225-00955

2023-09-01

Abstract:Objective: To investigate the effect and regulation of umbilical cord-derived mesenchymal stem cells (UC-MSCs) on islets function and NOD-like receptor family, pyrin domain containing 3 (NLRP3) and autophagy in type 2 diabetic mellitus (T2DM) mice. Methods: Experimental study. Twenty, 8-week-old, male C57BL/6J mice were selected and divided into a normal control group (n=5) and a high-fat feeding modeling group (n=15). The model of T2DM was established by high-fat feeding combined with intraperitoneal injection of low-dose streptozotocin. After successful modeling, those mice were divided into a diabetes group (n=7) and a UC-MSCs treatment group (n=7). The UC-MSCs treatment group was given UC-MSCs (1×106/0.2 ml phosphate buffer solution) by tail vein infusion once a week for a total of 4 weeks; the diabetes group was injected with the same amount of normal saline, and the normal control group was not treated. One week after the treatment, mice underwent intraperitoneal glucose tolerance tests and intraperitoneal insulin tolerance tests, and then the mice were sacrificed to obtain pancreatic tissue to detect the expressions of interleukin-1β (IL-1β) and pancreatic and duodenal homeobox 1 (PDX-1) by immunofluorescence. The bone marrow-derived macrophages were stimulated with lipopolysaccharide and adenosine triphosphate (experimental group) in vitro, then co-cultured with UC-MSCs for 24 h (treatment group). After the culture, enzyme-linked immunosorbent assay was used to detect the secretion level of IL-1β in the supernatant, and immunofluorescence staining was used to detect the expression of NLRP3 inflammasome, and related autophagy proteins. Statistical analysis was performed using unpaired one-way analysis of variance, repeated measure analysis of variance. Results: In vivo experiments showed that compared with the diabetes group, the UC-MSCs treatment group partially repaired islet structure, improved glucose tolerance and insulin sensitivity (all P<0.05), and the expression of PDX-1 increased and IL-1β decreased in islets under confocal microscopy. In vitro experiments showed that compared with the experimental group, the level of IL-1β secreted by macrophages in the treatment group was decreased [(85.9±74.6) pg/ml vs. (883.4±446.2) pg/ml, P=0.001], the expression of NLRP3 inflammasome and autophagy-related protein P62 was decreased, and the expressions of microtubule-associated protein 1 light chain 3β (LC3) and autophagy effector Beclin-1 were increased under confocal microscopy. Conclusions: UC-MSCs can reduce the level of pancreatic inflammation in T2DM mice, preserving pancreatic function. This might be associated with the ability of UC-MSCs to inhibit the activity of NLRP3 inflammasomes in macrophages and enhance autophagy levels.
Localization of Human Mesenchymal Stem Cells from Umbilical Cord Blood and Their Role in Repair of Diabetic Foot Ulcers in Rats

Qing-Song Zhao,Nan Xia,Nan Zhao,Ming Li,Chang-Long Bi,Qing Zhu,Guo-Fen Qiao,Zhi-Feng Cheng

DOI: https://doi.org/10.7150/ijbs.7237

2014-01-01

International Journal of Biological Sciences

Abstract:The aim of this study is to explore the localization of human mesenchymal stem cells from umbilical cord matrix (hMSCs-UC) and the role of these cells in the repair of foot ulcerate tissue in diabetic foot ulcers in rats. A diabetic rat model was established by administering Streptozotocin. Diabetic foot ulceration was defined as non-healing or delayed-healing of empyrosis on the dorsal hind foot after 14 weeks. hMSCs-UC were delivered through the left femoral artery. We evaluated the localization of hMSCs-UC and their role in tissue repair in diabetic foot ulcers by histological analysis, PCR, and immunohistochemical staining. A model for diabetes was established in 54 out of 60 rats (90% success rate) and 27 of these rats were treated with hMSCs-UC. The area of ulceration was significantly and progressively reduced at 7 and 14 days following treatment with hMSCs-UC. This gross observation was strongly supported by the histological changes, including newly developed blood vessels and proliferation of inflammatory cells at 3 days post-treatment, significant increase in granulation tissue at 7 days post-treatment and squamous epithelium or stratified squamous epithelium at 14 days post-treatment. Importantly, human leukocyte antigen type-I (HLA-1) was confirmed in ulcerated tissue by RT-PCR. The expression of cytokeratin 19 was significantly increased in diabetic model rats, with no detectable change in cytokeratin 10. Additionally, both collagens I and III increased in model rats treated with hMSCs-UC, but the ratio of collagen I/III was less significant in treated rats compared with control rats. These results suggest that hMSCs-UC specifically localize to the target ulcerated tissue and may promote the epithelialization of ulcerated tissue by stimulating the release of cytokeratin 19 from keratinocytes and extracellular matrix formation.

biochemistry & molecular biology
Reversion of early- and late-stage β-cell dedifferentiation by human umbilical cord-derived mesenchymal stem cells in type 2 diabetic mice

Bing Li,Yu Cheng,Yaqi Yin,Jing Xue,Songyan Yu,Jieqing Gao,Jiejie Liu,Li Zang,Yiming Mu

DOI: https://doi.org/10.1016/j.jcyt.2021.01.005

IF: 6.196

Cytotherapy

Abstract:Background aims: The authors aimed to observe β-cell dedifferentiation in type 2 diabetes mellitus (T2DM) and investigate the reversal effect of umbilical cord-derived mesenchymal stem cells (UC-MSCs) on early- and late-stage β-cell dedifferentiation. Methods: In high-fat diet (HFD)/streptozotocin (STZ)-induced T2DM mice, the authors examined the predominant role of β-cell dedifferentiation over apoptosis in the development of T2DM and observed the reversion of β-cell dedifferentiation by UC-MSCs. Next, the authors used db/db mice to observe the progress of β-cell dedifferentiation from early to late stage, after which UC-MSC infusions of the same amount were performed in the early and late stages of dedifferentiation. Improvement in metabolic indices and restoration of β-cell dedifferentiation markers were examined. Results: In HFD/STZ-induced T2DM mice, the proportion of β-cell dedifferentiation was much greater than that of apoptosis, demonstrating that β-cell dedifferentiation was the predominant contributor to T2DM. UC-MSC infusions significantly improved glucose homeostasis and reversed β-cell dedifferentiation. In db/db mice, UC-MSC infusions in the early stage significantly improved glucose homeostasis and reversed β-cell dedifferentiation. In the late stage, UC-MSC infusions mildly improved glucose homeostasis and partially reversed β-cell dedifferentiation. Combining with other studies, the authors found that the reversal effect of UC-MSCs on β-cell dedifferentiation relied on the simultaneous relief of glucose and lipid metabolic disorders. Conclusions: UC-MSC therapy is a promising strategy for reversing β-cell dedifferentiation in T2DM, and the reversal effect is greater in the early stage than in the late stage of β-cell dedifferentiation.
Role and effect of vein-transplanted human umbilical cord mesenchymal stem cells in the repair of diabetic foot ulcers in rats

Rongfeng Shi,Weishuai Lian,Yinpeng Jin,Chuanwu Cao,Shilong Han,Xiaohu Yang,Suming Zhao,Maoquan Li,Hui Zhao

DOI: https://doi.org/10.1093/abbs/gmaa039

IF: 3.7

2020-06-01

Acta Biochimica et Biophysica Sinica

Abstract:Abstract Diabetic foot ulcer (DFU) is one of diabetic complications, which is frequently present and tormented in diabetes mellitus. Most multipotent mesenchymal stromal cells (MSCs) are capable of immune evasion, providing an allogeneic, ready-to-use, cell product option for therapeutic applications. The beneficial effect of MSCs for the treatment of a variety of traumatic injuries, such as open wounds, has been extensively explored. In this study, a rat DFU model was used to simulate the pathophysiology of clinical patients and to investigate the localization of human umbilical cord mesenchymal stem cells (hUC-MSCs) after intravenous transplantation and its role in DFU healing, so as to evaluate the potential of hUC-MSCs in the treatment of DFU. The diabetic rat model was established by streptozotocin injection, which was used to create full-thickness foot dorsal skin wounds to mimic DFU by a 6-mm skin biopsy punch and a Westcott scissor. The hUC-MSCs were transplanted through femoral vein, and the ulcer cicatrization situation and the fate of hUC-MSCs were evaluated. Our data suggest that intravenously transplantated hUC-MSCs have the ability to migrate and locate to the wound tissue and are helpful to wound healing in DFU rats, partly by regulating inflammation, trans-differentiation and providing growth factors that promote angiogenesis, cell proliferation and collagen deposition. Herein, we demonstrate that hUC-MSC transplantation is able to accelerate DFU healing in rats and transplantation of exogenous stem cells may be a potential strategy for clinical application in DFUs.

biochemistry & molecular biology,biophysics
Comparison of the Efficacy and Safety of Non-Myeloablative Autologous Peripheral Hematopoietic Stem Cell and Single Allogeneic Umbilical Cord Mesenchymal Stem Cell Transplantation in the Treatment of Patients with Type 1 Diabetes Mellitus

庞建波,陆婧,沈山梅,张溦,李莉蓉,毕艳,朱大龙

DOI: https://doi.org/10.3760/cma.j.cn115791-20220627-00302

2023-01-01

Abstract:Objective:To explore the efficacy and safety of non-myeloablative autologous peripheral hematopoietic stem cell (HSC) and single allogeneic umbilical cord mesenchymal stem cell (MSC) transplantation in the treatment of patients with type 1 diabetes mellitus (T1DM).Methods:This was a retrospective case-control study. Nine participants receiving HSC transplantation and 8 participants receiving MSC transplantation during August 2006 and December 2010 in Department of Endocrinology, Nanjing Drum Tower Hospital Clinical College of Xuzhou Medical University were selected for analysis, meanwhile 10 matched participants who received insulin therapy alone during the same time period were enrolled as the control. Insulin injection dose, glycated hemoglobin A 1c (HbA 1c), fasting C-peptide (FCP) and 2h-postprandial C-peptide (2hCP) were collected before and 12 months after transplantation, and the change range of each index was calculated. Clinical remission was defined as a 10% increase from baseline in the levels of FCP and/or 2hCP. The adverse reactions of patients during the two kinds of stem cell transplantation and follow-up were observed to judge their safety. T-test, one-way analysis of variance, Mann-Whitney U test, Kruskal-Wallis H test, Fisher′s exact test were used to compare between the groups. Results:At the 12 th month of follow-up, the ratio of clinical remission in the HSC-treated, MSC-treated and control group were 7/9, 2/8, and 1/10 respectively, with HSC-treated group showing significantly higher ratio than that of control group ( P=0.005). By the end of follow-up, the HbA 1c of the three groups were (6.5±1.3)%, (7.7±1.5)% and (9.2±3.5)%, respectively. The decrease of insulin injection dose and increase of FCP in HSC transplantation group were significantly higher than those in control group, and the increase of 2hCP in HSC transplantation group was significantly higher than that in MSC transplantation group and control group ( P<0.05). Two recipients of HSC-treated group achieved insulin independence, but none in the MSC-treated group or control group. Compared to baseline in each group, HbA 1c ( t=-3.85, P=0.008) and insulin injection dose ( t=-2.47, P=0.039) were decreased and 2hCP ( Z=-2.07, P=0.039) were increased at the end of follow-up in HSC-treated group, while HbA 1c ( t=-3.11, P=0.017) and 2hCP ( Z=-2.38, P=0.016) were decreased in MSC-treated group. Considering the safety of stem cell transplantation, all recipients in the HSC-treated group experienced some adverse events, while none presented in the MSC-treated group. Conclusions:Both stem cell therapies improved glycemic control and preserved residue β-cell function in T1DM patients. HSC transplantation had a tendency to be superior to MSC transplantation in improving β-cell function, while the latter presented a higher safety profile.
Human umbilical cord-derived mesenchymal stem cells ameliorate insulin resistance via PTEN-mediated crosstalk between the PI3K/Akt and Erk/MAPKs signaling pathways in the skeletal muscles of db/db mice

Guang Chen,Xiao-yan Fan,Xiao-peng Zheng,Yue-lei Jin,Ying Liu,Shuang-chun Liu

DOI: https://doi.org/10.21203/rs.2.24329/v1

2020-01-01

Abstract:Abstract Background: Globally, 1 in 11 adults have diabetes mellitus and 90% of the cases are type 2 diabetes mellitus (T2DM). Asia is the epicenter of this global T2DM epidemic. T2DM and its complications have contributed significantly to the burden of mortality and disability worldwide. Insulin resistance (IR) is a central defect in T2DM, and although multiple drugs have been developed to ameliorate IR, the limitations and accompanying side effects cannot be ignored. Thus more effective methods are required to improve IR.Methods: In the current study, db/m and db/db mice were injected with human umbilical cord-derived mesenchymal stem cells (HUC-MSCs) via tail vein injection (IV), intraperitoneal injection (IP) and skeletal muscle injection (IM). Body weight, fasting blood glucose and the survival rates were monitored. Furthermore, the anti-IR effects and potential mechanisms of transplanted HUC-MSCs were investigated in db/db mice in vivo.Results: The results showed that HUC-MSC transplantation by IM was safer compared with IV and IP, and the survival rate reached 100% in the IM transplanted mice. HUC-MSCs can stabilize localization and differentiation in skeletal muscle tissue and significantly ameliorate IR. Potential regulatory mechanisms are associated with downregulation of inflammation; regulating the balance between PI3K/Akt and ERK/MAPK signaling pathway via PTEN, but was not associated with the IGF-1/IGF-1R signaling pathway.Conclusions: These results suggest HUC-MSC transplantation by IM may be a novel therapeutic direction to prevent IR and increase insulin sensitivity.
Action of human umbilical cord mesenchymal stem cells by intra-arterial transplantation for treatment of type 2 diabetic Beagle dogs

Song DONG,Hong WANG,Lei LEI,Han SHI,Yizhong WANG

2017-01-01

Abstract:Objective To investigate the therapeutic effects of human umbilical cord mesenchymal stem cells (UCMSCs) transplanted into a dog model of type 2 diabetes mellitus (T2DM) via the arterial intervention.Methods 24 Beagle dogs were randomly divided into UCMSCs treatment group (treatment group,n =11),diabetic model control group (model group,n =8) and normal control group (normal group,n =5).Dogs in treatment and model control group were fed on high fat diet and intravenously injected with alloxan to establish T2DM models.Treatment group accepted insulin therapy and UCMSCs transplantation via arterial intervention.Model group only received insulin therapy,and normal group did not receive any treatment.Distribution of UCMSCs traced by CM-Dil was observed under fluorescence microscope.In addition,the three groups were compared with body mass,blood fat,fasting plasma glucose,insulin dosage,Area under the curve of C-peptide,insulin secretion index (HOMA-β),insulin resistance index (HOMA-IR) before and after therapy.Results The cells traced by CM-Dil mainly distributed in the pancreas and kidney.At 4 weeks after transplantation,fasting plasma glucose and insulin dosage were decreased gradually in treatment group,up to 12 weeks average daily insulin dose was declined from (27.94±1.86) U to (15.02±2.90) U.Compared with the model group,at 12 weeks triglyceride,low density lipoprotein cholesterol,HOMA-IR decreased (P ＜ 0.05),under the curve of C-peptide,HOMA-β increased in treatment group (P ＜ 0.05).Conclusion The method of translation of UCMSCs by artery intervention not only maximum guarantee the stem cells quantity into the pancreas,but also has great effects on reversing glucose and lipid metabolism disorder,recovering islet β cell function,decreasing insulin dosage,and relieving insulin resistance.
Human umbilical cord mesenchymal stem cells in type 2 diabetes mellitus: the emerging therapeutic approach

Andreia Gomes,Pedro Coelho,Raquel Soares,Raquel Costa

DOI: https://doi.org/10.1007/s00441-021-03461-4

Abstract:The umbilical cord has been proved to be an easy-access, reliable, and useful source of mesenchymal stem cells (MSC) for clinical applications due to its primitive, immunomodulatory, non-immunogenic, secretory and paracrine, migratory, proliferative, and multipotent properties. This set of characteristics has recently attracted great research interest in the fields of nanotechnology and regenerative medicine and cellular therapy. Accumulating evidence supports a pronounced therapeutic potential of MSC in many different pathologies, from hematology to immunology, wound-healing, tissue regeneration, and oncology. Diabetes mellitus, branded the epidemic of the century, is considered a chronic metabolic disorder, representing a major burden for health system sustainability and an important public health challenge to modern societies. The available treatments for type 2 diabetes mellitus (T2DM) still rely mainly on combinations of oral antidiabetic agents with lifestyle and nutritional adjustments. Despite the continuous development of novel and better hypoglycemic drugs, their efficacy is limited in the installment and progression of silent T2DM complications. T2DM comorbidities and mortality rates still make it a serious, common, costly, and long-term manageable disease. Recently, experimental models, preclinical observations, and clinical studies have provided some insights and preliminary promising results using umbilical cord MSCs to treat and manage diabetes. This review focuses on the latest research and applications of human-derived umbilical cord MSC in the treatment and management of T2DM, exploring and systematizing the key effects of both umbilical cord MSC and its factor-rich secretome accordingly with the major complications associated to T2DM.

Blocking of nonspecific IgG in indirect radioimmunoassay for detecting Ascaris suum antigens.

Safety evaluation of human umbilical cord-mesenchymal stem cells in type 2 diabetes mellitus treatment: A phase 2 clinical trial

Therapeutic Efficacy Of Umbilical Cord-Derived Mesenchymal Stem Cells In Patients With Type 2 Diabetes

Study of The Phytochemical Analysis And Antimicrobial Activity of Dodonaea Viscosa

Effect of Htimp-1 Overexpression in Human Umbilical Cord Mesenchymal Stem Cells on the Repair of Pancreatic Islets in Type-1 Diabetic Mice

Efficacy of Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Type 2 Diabetes Assessed by Retrospective Continuous Glucose Monitoring

Umbilical cord mesenchymal stem cells transplantation for newly-onset type 1 diabetes

Clinical efficacy of autologous stem cell transplantation for the treatment of patients with type 2 diabetes mellitus: a meta-analysis.

Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial

Stem cell transplantation for the treatment of diabetic foot

Umbilical cord blood stem cell transplantation for the treatment of diabetic foot in 23 cases

Comparison of therapeutic effects of mesenchymal stem cells from umbilical cord and bone marrow in the treatment of type 1 diabetes

Human umbilical cord-derived mesenchymal stem cell transplantation for treatment for onset type 1 diabetes mellitus

[The impact of human umbilical cord-derived mesenchymal stem cells on the pancreatic function of type 2 diabetic mice and their regulatory role on NLRP3 inflammasomes]

Localization of Human Mesenchymal Stem Cells from Umbilical Cord Blood and Their Role in Repair of Diabetic Foot Ulcers in Rats

Reversion of early- and late-stage β-cell dedifferentiation by human umbilical cord-derived mesenchymal stem cells in type 2 diabetic mice

Role and effect of vein-transplanted human umbilical cord mesenchymal stem cells in the repair of diabetic foot ulcers in rats

Comparison of the Efficacy and Safety of Non-Myeloablative Autologous Peripheral Hematopoietic Stem Cell and Single Allogeneic Umbilical Cord Mesenchymal Stem Cell Transplantation in the Treatment of Patients with Type 1 Diabetes Mellitus

Human umbilical cord-derived mesenchymal stem cells ameliorate insulin resistance via PTEN-mediated crosstalk between the PI3K/Akt and Erk/MAPKs signaling pathways in the skeletal muscles of db/db mice

Action of human umbilical cord mesenchymal stem cells by intra-arterial transplantation for treatment of type 2 diabetic Beagle dogs

Human umbilical cord mesenchymal stem cells in type 2 diabetes mellitus: the emerging therapeutic approach